Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors

Zhen Wang, Yali Zhang, Sergio G. Bartual, Jinfeng Luo, Tingting Xu, Wenting Du, Qiuju Xun, Zhengchao Tu, Rolf A. Brekken, Xiaomei Ren, Alex N. Bullock, Guang Liang, Xiaoyun Lu, Ke Ding

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Acute lung injury (ALI) is a deadly symptom for serious lung inflammation. Discoidin Domain Receptor 1 (DDR1) is a new potential target for anti-inflammatory drug discovery. A new selective tetrahydroisoquinoline-7-carboxamide based DDR1 inhibitor 7ae was discovered to tightly bind the DDR1 protein and potently inhibit its kinase function with a Kd value of 2.2 nM and an IC50 value of 6.6 nM, respectively. The compound dose-dependently inhibited lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) release in mouse primary peritoneal macrophages (MPMs). In addition, 7ae also exhibited promising in vivo anti-inflammatory effects in a LPS-induced mouse ALI model. To the best of our knowledge, this is the first “proof of concept” investigation on the potential application of a small molecule DDR1 inhibitor to treat ALI.

Original languageEnglish (US)
Pages (from-to)327-332
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume8
Issue number3
DOIs
StatePublished - Mar 9 2017

Fingerprint

Tetrahydroisoquinolines
Lipopolysaccharides
Acute Lung Injury
Anti-Inflammatory Agents
Derivatives
Macrophages
Interleukin-6
Phosphotransferases
Tumor Necrosis Factor-alpha
Molecules
Peritoneal Macrophages
Drug Discovery
Inhibitory Concentration 50
Pneumonia
Proteins
Discoidin Domain Receptor 1

Keywords

  • acute lung injury (ALI)
  • DDR1
  • inflammation
  • inhibitor
  • structure−activity relationship (SAR)

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry

Cite this

Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. / Wang, Zhen; Zhang, Yali; Bartual, Sergio G.; Luo, Jinfeng; Xu, Tingting; Du, Wenting; Xun, Qiuju; Tu, Zhengchao; Brekken, Rolf A.; Ren, Xiaomei; Bullock, Alex N.; Liang, Guang; Lu, Xiaoyun; Ding, Ke.

In: ACS Medicinal Chemistry Letters, Vol. 8, No. 3, 09.03.2017, p. 327-332.

Research output: Contribution to journalArticle

Wang, Z, Zhang, Y, Bartual, SG, Luo, J, Xu, T, Du, W, Xun, Q, Tu, Z, Brekken, RA, Ren, X, Bullock, AN, Liang, G, Lu, X & Ding, K 2017, 'Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors', ACS Medicinal Chemistry Letters, vol. 8, no. 3, pp. 327-332. https://doi.org/10.1021/acsmedchemlett.6b00497
Wang, Zhen ; Zhang, Yali ; Bartual, Sergio G. ; Luo, Jinfeng ; Xu, Tingting ; Du, Wenting ; Xun, Qiuju ; Tu, Zhengchao ; Brekken, Rolf A. ; Ren, Xiaomei ; Bullock, Alex N. ; Liang, Guang ; Lu, Xiaoyun ; Ding, Ke. / Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. In: ACS Medicinal Chemistry Letters. 2017 ; Vol. 8, No. 3. pp. 327-332.
@article{8fc7b14ae64e47af832cf4bc0daa7f0d,
title = "Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors",
abstract = "Acute lung injury (ALI) is a deadly symptom for serious lung inflammation. Discoidin Domain Receptor 1 (DDR1) is a new potential target for anti-inflammatory drug discovery. A new selective tetrahydroisoquinoline-7-carboxamide based DDR1 inhibitor 7ae was discovered to tightly bind the DDR1 protein and potently inhibit its kinase function with a Kd value of 2.2 nM and an IC50 value of 6.6 nM, respectively. The compound dose-dependently inhibited lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) release in mouse primary peritoneal macrophages (MPMs). In addition, 7ae also exhibited promising in vivo anti-inflammatory effects in a LPS-induced mouse ALI model. To the best of our knowledge, this is the first “proof of concept” investigation on the potential application of a small molecule DDR1 inhibitor to treat ALI.",
keywords = "acute lung injury (ALI), DDR1, inflammation, inhibitor, structure−activity relationship (SAR)",
author = "Zhen Wang and Yali Zhang and Bartual, {Sergio G.} and Jinfeng Luo and Tingting Xu and Wenting Du and Qiuju Xun and Zhengchao Tu and Brekken, {Rolf A.} and Xiaomei Ren and Bullock, {Alex N.} and Guang Liang and Xiaoyun Lu and Ke Ding",
year = "2017",
month = "3",
day = "9",
doi = "10.1021/acsmedchemlett.6b00497",
language = "English (US)",
volume = "8",
pages = "327--332",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors

AU - Wang, Zhen

AU - Zhang, Yali

AU - Bartual, Sergio G.

AU - Luo, Jinfeng

AU - Xu, Tingting

AU - Du, Wenting

AU - Xun, Qiuju

AU - Tu, Zhengchao

AU - Brekken, Rolf A.

AU - Ren, Xiaomei

AU - Bullock, Alex N.

AU - Liang, Guang

AU - Lu, Xiaoyun

AU - Ding, Ke

PY - 2017/3/9

Y1 - 2017/3/9

N2 - Acute lung injury (ALI) is a deadly symptom for serious lung inflammation. Discoidin Domain Receptor 1 (DDR1) is a new potential target for anti-inflammatory drug discovery. A new selective tetrahydroisoquinoline-7-carboxamide based DDR1 inhibitor 7ae was discovered to tightly bind the DDR1 protein and potently inhibit its kinase function with a Kd value of 2.2 nM and an IC50 value of 6.6 nM, respectively. The compound dose-dependently inhibited lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) release in mouse primary peritoneal macrophages (MPMs). In addition, 7ae also exhibited promising in vivo anti-inflammatory effects in a LPS-induced mouse ALI model. To the best of our knowledge, this is the first “proof of concept” investigation on the potential application of a small molecule DDR1 inhibitor to treat ALI.

AB - Acute lung injury (ALI) is a deadly symptom for serious lung inflammation. Discoidin Domain Receptor 1 (DDR1) is a new potential target for anti-inflammatory drug discovery. A new selective tetrahydroisoquinoline-7-carboxamide based DDR1 inhibitor 7ae was discovered to tightly bind the DDR1 protein and potently inhibit its kinase function with a Kd value of 2.2 nM and an IC50 value of 6.6 nM, respectively. The compound dose-dependently inhibited lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) release in mouse primary peritoneal macrophages (MPMs). In addition, 7ae also exhibited promising in vivo anti-inflammatory effects in a LPS-induced mouse ALI model. To the best of our knowledge, this is the first “proof of concept” investigation on the potential application of a small molecule DDR1 inhibitor to treat ALI.

KW - acute lung injury (ALI)

KW - DDR1

KW - inflammation

KW - inhibitor

KW - structure−activity relationship (SAR)

UR - http://www.scopus.com/inward/record.url?scp=85014965915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014965915&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.6b00497

DO - 10.1021/acsmedchemlett.6b00497

M3 - Article

C2 - 28337325

AN - SCOPUS:85014965915

VL - 8

SP - 327

EP - 332

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 3

ER -